Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.

about

Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.

P2860

Q38972808-9CBC3519-94EF-4199-A988-7F4136204533

P2860

Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.

Item

http://www.wikidata.org/entity/Q40401733

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pharmacological inhibition of ...... st experimental leishmaniasis.

@en

type

Item

label

Pharmacological inhibition of ...... st experimental leishmaniasis.

@en

prefLabel

Pharmacological inhibition of ...... st experimental leishmaniasis.

@en

P1476

Pharmacological inhibition of ...... st experimental leishmaniasis.

@en

P2093

Aida Feiz Barazandeh

http://www.w3.org/2001/XMLSchema#string

Dong Liu

http://www.w3.org/2001/XMLSchema#string

Forough Khadem

http://www.w3.org/2001/XMLSchema#string

Jude E Uzonna

http://www.w3.org/2001/XMLSchema#string

Ping Jia

http://www.w3.org/2001/XMLSchema#string

Zhirong Mou

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K isoform-selective inhibitors: next-generation targeted cancer therapies

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

Health economic evaluations of visceral leishmaniasis treatments: a systematic review

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis

Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors

A current perspective on leishmaniasis

Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.

P304

467-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW448

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yoav Keynan

P577

2016-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27999013

http://www.w3.org/2001/XMLSchema#string

Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.

about

P2860

P2860

Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698